693 results on '"Cervantes, F."'
Search Results
2. A new mouse of the Peromyscus maniculatus species complex (Cricetidae) from the highlands of central Mexico
3. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
4. A rural environment does not protect against asthma or other allergic diseases amongst Mexican children
5. Novel application of magnetic nano-carbon composite as redox mediator in the reductive biodegradation of iopromide in anaerobic continuous systems
6. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
7. Order-fractal transitions in abstract paintings
8. Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations
9. Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients
10. Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
11. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists
12. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both
13. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
14. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
15. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
16. Concurrence of Anaerobic Ammonium Oxidation and Organotrophic Denitrification in Presence of p-Cresol
17. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
18. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
19. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
20. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis
21. Ruxolitinib and survival improvement in patients with myelofibrosis
22. Spanish Sign Language Interpreter for Mexican Linguistics
23. Mutations and prognosis in primary myelofibrosis
24. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
25. IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis
26. Relación entre el día de colección y la recuperación de embriones en alpacas superovuladas
27. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
28. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders
29. Subtraction of test mass angular noise in the LISA technology package interferometer
30. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients
31. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group
32. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution
33. Efecto del estadío del desarrollo folicular al momento de la monta sobre la ovulación y supervivencia embrionaria en alpacas
34. Mortality due to lung cancer in Mexico
35. Coding sequence and intron–exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients
36. Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
37. Quinone-respiration improves dechlorination of carbon tetrachloride by anaerobic sludge
38. Azo dye reduction by thermophilic anaerobic granular sludge, and the impact of the redox mediator anthraquinone-2,6-disulfonate (AQDS) on the reductive biochemical transformation
39. Successful treatment by selective arterial embolization of severe retroperitoneal hemorrhage secondary to bone marrow biopsy in post-polycythemic myelofibrosis
40. The Omiltemi rabbit (Sylvilagus insonus) is not extinct
41. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia
42. Single-agent therapy with oral mercaptopurine for nonlymphoid blast crisis of chronic myeloid leukemia
43. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status
44. Leukemia risk models in primary myelofibrosis: an International Working Group study
45. Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia
46. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients
47. Inactivating mutations of the histone methyltransferase EZH2 in myeloid disorders: V420
48. Repatriations to Guadalajara: An Experience of Collaboration between a Faith-based Organization and the Government.
49. Concentración preoperatoria de fibrinógeno plasmático como predictor de sangrado en artroplastía total de cadera.
50. Re: Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Alvarez-Larrán A et al
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.